Essential Partners’s Generation Bio GBIO Stock Holding History

Essential Partners’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13	Closed	-$42	–	2712
2025 Q2	$42	Buy	+13	New	+$50	﹤0.01%	2160

Other funds holding GBIO

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Essential Partners's GBIO Position: Q3 2025 in Review

Essential Partners sold out of Generation Bio (GBIO) in Q3 2025, closing a stake of 13 shares — an estimated $42 sold.

Essential Partners first reported a position in GBIO in Q2 2025 and held it in 1 quarter. The position peaked at $42 in Q2 2025. 41 funds tracked by Wall St. Rank hold GBIO as of Q3 2025.

Essential Partners reported no remaining Generation Bio position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 13 Generation Bio shares in Q3 2025, an estimated $42.
Essential Partners first reported a position in Generation Bio in Q2 2025 and held it in 1 quarter.
Essential Partners's Generation Bio position peaked at $42 in Q2 2025.
41 funds tracked by Wall St. Rank held Generation Bio as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.